Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06556615
Recruiting Observational

Health Related Quality of Life (HrQoL) in Classical Homocystinuria (CBS Deficiency)

NCT06556615 · tracked via the Priya Life Science Switzerland tracker
Sponsor
University Children's Hospital, Zurich
Phase
Observational
Started
2025-01-15
Last updated
2025-04-10

Condition(s) studied

Homocystinuria

Investigational drug(s) / intervention(s)

Interview

Interview: Interviews, presentation of questionnaires

Study summary

Patients, parents of young / handicapped patients, and experts will be interviewed to collect contents relevant for HrQoL in CBS deficiency. Based on these data, a questionnaire will be developed and tested for comprehensibility in patients and parents of young / handicapped patients. A final questionnaire version will be tested for psychometric criteria including validity and reliability.

Eligibility

Sex
ALL
Min age
8 Years
Max age
—
Healthy volunteers
No
Inclusion criteria * Patients with CBS deficiency from age 8 years * Parents of patient(s) \< 18 years with cognitive impairment * Parents of patients between age 4 and 7 * Experts on CBS deficiency * Able to give informed consent as documented by signature Exclusion criteria \- Sufficient command of the German or the English language

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kinderspital Zürich Zurich Switzerland Recruiting

More University Children's Hospital, Zurich trials in Switzerland

Short and Long-arm Fiberglass Cast Immobilization for Distal Salter Harris I and II Forearm Fractures in Children Recruiting
Borrelia B-cell Diagnostics Recruiting
The Swiss Neurodevelopmental Outcome Registry for Children With CHD Recruiting
An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children Recruiting
The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06556615 on ClinicalTrials.gov ↗ ← All trials in Switzerland